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1. INTRODUCTION {#ptr6767-sec-0001}
===============

Botanical character of *Rosa rugosa* Thunb., (*R. rugosa*) occurs naturally in Eastern Asia from ochotsk to Korea and the northern parts of Japan to China. Traditionally, *R. rugosa* extracts of the flowers or hips have been valued for Asian culinary, cosmetic, aromatherapy, and medicinal properties and used in herbal medicines for diabetes mellitus and osteoarthritis (Cho, Yokozawa, Kim, Shibahara, & Park, 2004; Yang et al., [2016](#ptr6767-bib-0035){ref-type="ref"}). The several effects seemed to be involved in the presence of many phytochemicals in *R. rugosa* extracts, such as flavonoids, phenylpropanoid, bisabolanes, acoranes, tannins, fatty acid, and terpenoids (Hashidoko, [1996](#ptr6767-bib-0009){ref-type="ref"}). Among these natural products, terpenoids were included in several medicinal plants such as *Dysoxylum gotadhora*, *Cyperus rotaundus*, *Dodonaea viscosa*, *Onopordum Illyricum*, and *Gardenia sootepenis* and reacted as anti‐inflammatory agent (Dang, Parekar, Kamat, Scindia, & Rege, [2011](#ptr6767-bib-0005){ref-type="ref"}; Formisano et al., [2017](#ptr6767-bib-0006){ref-type="ref"}; Jiang et al., [2015](#ptr6767-bib-0017){ref-type="ref"}; Khalil, Sperotto, & Manfron, [2006](#ptr6767-bib-0018){ref-type="ref"}; Youn et al., [2016](#ptr6767-bib-0036){ref-type="ref"}). A concomitant feature of anti‐inflammatory activity among the exhibited medicinal plants was down‐regulation associated with nuclear factor kappa B (NF‐κB), or signal transducer and activator of transcription 3 (STAT3), as a transcription factor.

NF‐κB and STAT3 signaling mainly had known to regulate several biological interactions; development, proliferation, differentiation as well as cancer and inflammation (He & Karin, [2011](#ptr6767-bib-0012){ref-type="ref"}). In perspectives of inflammatory action, NF‐κB acts on a family of inducible transcription factors that regulate a lot of genes associated with individual functional processes in inflammation in innate immune cells, including macrophages (Oeckinghaus & Ghosh, [2009](#ptr6767-bib-0024){ref-type="ref"}). In addition, STAT3 is involved in a family of cytoplasmic protein with SH2 (Src Homology‐2) domains. They act as signal messengers and transcription factors and participate in normal cellular response to growth factors and cytokines (Guanizo, Fernando, Garama, & Gough, [2018](#ptr6767-bib-0007){ref-type="ref"}). when activate both NF‐κB and STAT3 signaling, genes responsible for inflammation including IL‐6 (interleukin‐6), IL‐10 (interleukin‐10), IL‐11 (interleukin‐11), IL‐17 (interleukin‐17), IL‐23 (interleukin‐23), IL‐1b (interleukin‐1b), Tnf‐α (tumor necrosis factor‐α), and iNOS (inducible nitric oxide synthase) were induced and regulated in pathogenesis of inflammation diseases (Liu et al., [2017](#ptr6767-bib-0021){ref-type="ref"}; He & Karin, [2011](#ptr6767-bib-0012){ref-type="ref"}). Thus, the safe development of inhibitory agents of activation both NF‐κB, and STAT3 is crucial for clinical treatment of inflammatory diseases among natural constituents.

In present study, we newly investigated anti‐inflammatory effects of *R. rugosa* extracts (EtOH 95%) and developed effective compounds under inflammatory condition associated with lipopolysaccharides (LPS) and IL‐6‐mediated inflammation. Although *R. rugosa* flower extracts (EtOH 50%) and euscaphic acid, derived from *R. rugosa* root extracts performed anti‐inflammatory and effects in previous study (Um, Han, & Lee, [2018](#ptr6767-bib-0031){ref-type="ref"}), there were no academic evaluation for information of ingredients and quantitative analysis among *R. rugosa* extracts. Here, we further studied that anti‐inflammatory agents of terpenoid structures (compound **1** to **13**) and originally reported the identification of a new compound, 11‐methoxy polisin A and 13‐methoxy bisaborosaol F from the *R. rugosa* extracts (EtOH 95%) using spectroscopic data, including nuclear magnetic resonance (NMR) and electrospray ionization mass spectrometry (ESI‐MS). In several phytochemical constituents of *R. rugosa* extracts (EtOH 95%), our group originally reported that rugosic acid A, sesquiterpenoid structure, had anti‐inflammatory effects by amelioration of nitric oxide (NO) production and inhibition of nuclear‐translocation of NF‐κB under LPS‐mediated inflammatory conditions in RAW 264.7. In addition, rugosic acid A significantly disturbed IL‐6‐mediated STAT3 activation under IL‐6/STAT3 screening system. Finally, we tested RA‐mediated amelioration of inflammation in LPS‐mediated acute lung injury as an acute pneumonia model, which was similar to severe acute respiratory syndrome by coronavirus such as COVID‐19 pneumonia (Zhao et al., [2020](#ptr6767-bib-0037){ref-type="ref"}; Bernheim et al., [2020](#ptr6767-bib-0002){ref-type="ref"}). Through our results, RA expect to be alternative natural agent and treatment for acute pneumonia similar to COVID‐19 pneumonia.

2. MATERIALS AND METHODS {#ptr6767-sec-0002}
========================

2.1. General experimental procedures {#ptr6767-sec-0003}
------------------------------------

^1^H, ^13^C and 2D NMR spectra were acquired with instruments of a JEOL JNM‐ECA 400 and JEOL JNM‐ECA 600 instruments (JEOL, Tokyo, Japan) using TMS as an internal standard. Optical rotations were obtained on a Jasco P‐2000 polarimeter (Jasco Corp., Tokyo, Japan), and UV spectra were recorded using a SpectraMax M~2~ ^e^ spectrophotometer (Molecular Devices, Sunnyvale, CA). High resolution electrospray ionization mass spectrometer (HRESIMS) data were acquired using a Waters SYNAPT G2‐Si HDMS spectrometer (Waters, Milford, MA). Silica gel (Kieselgel 60, 230--400 mesh, Merck, Darmstadt, Germany) column chromatography (CC) and medium‐pressure liquid chromatography (MPLC, CombiFlash RF, Teledyne lsco, Lincoln, NE) were used to separate the extract fractions. Each fractions was monitored by TLC using silica gel 60 F~254~ and RP‐18 F~254s~ (Merck, Burlington). Sephadex LH‐20 (GE Healthcare, Uppsala, Sweden) column chromatography (CC) and semipreparative high speed liquid chromatography (semipreparative HPLC) were used to acquire pure compounds. Semipreparative HPLC was performed on a Shimadzu LC‐6 AD instrument (Shimadzu Corp., Tokyo, Japan) equipped with an SPD‐20A detector and Phenomenex Luna C18 (21.2 mm × 150 mm, 5 μm), Phenomenex Luna C18 (21.2 mm × 250 mm, 5 μm) columns. All fractions and compounds were analyzed using an Agilent 1,260 series HPLC system (Agilent, Santa Clara).

2.2. Extraction and isolation {#ptr6767-sec-0004}
-----------------------------

The dried *Rosa. rugosa* Thunb. (2.5 kg) was purchased from the acote co., ltd in Gochang, Korea. *R. rugosa* Thunb. (2.5 kg) dry powder was extracted twice with 95% ethanol (3 × 25 L) at 70°C and the EtOH solution was concentrated under vacuum to yield a pinkish brown residue (375.9 g). The residue (375.9 g) was suspended in H~2~O (1 L), and the aqueous layer was partitioned with *n*‐hexane, chloroform, ethyl acetate, and *n*‐buthanol. The *n*‐hexane layer (30.8 g) was subjected to silica gel column eluted with *n*‐hexane: EtOAc (1:0 to 0:1, *v/v*) to obtain fifteen fractions (H1 \~ H15). Fraction H11 (2.78 g) was subjected to MPLC \[column: C18 RediSepRf (130 g); mobile phase: H~2~O: MeOH (40 \~ 85%)\] to yield 13 fractions (H11‐1 \~ 13). Fraction H11‐3 and H11‐5 were subjected to preparative HPLC (Phenomenex Luna C18 column (150 × 21.2 mm, 5 μm). Fraction H11‐3 (57.4 mg) was used isocratic elution 50% CH~3~CN in H~2~O to afford compound **3** (t~*R*~ 25 min, 18.1 mg, 88.4% area). Fraction H11‐5 (68 mg) was used isocratic elution 40% CH~3~CN in H~2~O to afford compound **2** (t~*R*~55 min, 15.6 mg, 85.7% area). Fraction H12 (3.65 g) was subjected to MPLC \[column: C18 RediSepRf (130 g); mobile phase: H~2~O: MeOH (20 \~ 85%)\] to yield 15 fractions (H12‐1 \~ 15). Fraction H12‐6 (13.4 mg) was used isocratic elution 55% CH~3~CN in H~2~O to afford compound **7** (t~*R*~ 15 min, 2.7 mg, 92.2% area). Fraction H13 (1.21 g) was subjected to MPLC \[column: C18 RediSepRf (130 g); mobile phase: H~2~O: MeOH (35 \~ 100%)\] to yield eight fractions (H13‐1 \~ 8). The extracts contained appreciable levels of compound **7** content (0.8 mg/g extract). Fraction H13‐1 (53.6 mg) was used isocratic elution 48% CH~3~CN in H~2~O to afford compound **1** (t~*R*~ 16 min, 2.0 mg, 85.1% area). Fraction H15 (520.4 mg) was subjected to chromatography a C18 MPLC \[column: C18 RediSepRf (130 g)\] with a gradient solvent composed of H~2~O and MeOH (1:0 to 0:1, *v/v*), (30--100%)\] to generate 8 fractions (H15‐1 \~ 8). Compound **4** (3.4 mg, 86.8% area) and **6** (1.5 mg, 90.0% area) were purified from fraction H15‐2 (23 mg) by semi‐preparative HPLC (Phenomenex Luna 5 μm C18, 250 × 21.2 mm, 35% CH~3~CN) at 42 and 47 min.

The chloroform layer (18.6 g) was subjected to silica gel column eluted with CHCl~3~: MeOH to obtain 14 fractions (C1 \~ C14) and purify compound **9** (t~*R*~ 13 min, 9.1 mg, 81.6% area). Fraction C6 (172.3 mg) was subjected to MPLC \[column: C18 RediSepRf (26 g); mobile phase: H~2~O: MeOH (30 \~ 90%)\] to yield 11 fractions (C6‐1 \~ 11). Fraction C6‐7 (14.9 mg) was subjected to preparative HPLC (Phenomenex Luna C18 column (150 × 21.2 mm, 5 μm), using isocratic elution 50% CH~3~CN in H~2~O to afford compound **5** (t~*R*~ 43 min, 2.1 mg, 80.3% area). Compound **10** (3.0 mg, 79.2% area) was purified from fraction C6‐11 (30.1 mg) by semi‐preparative HPLC (Phenomenex Luna 5 μm C8, 150 × 21.2 mm, 80% CH~3~CN) at 27 min. Fraction C11 (1.8 g) was subjected to MPLC \[column: Silica RediSepRf (120 g); mobile phase: *n*‐hexane: EtOAc (1:0 to 0:1, *v/v*)\] to yield 13 fractions (C11‐1 \~ 13). Fraction C11‐12 (321.4 mg) was subjected to preparative HPLC (Phenomenex Luna C18 column \[250 × 21.2 mm, 5 μm\], using isocratic elution 70% CH~3~CN in H~2~O) to purify compound **8** (t~*R*~ 14 min, 26.7 mg, 86.9% area), **11** (t~*R*~ 48 min, 12.3 mg, 94.3% area). Fraction C11‐13 (190.5 mg) was subjected to preparative HPLC (Phenomenex Luna C18 column \[250 × 21.2 mm, 5 μm\], using isocratic elution 35, 80% CH~3~CN in H~2~O) to obtain two fractions (C11‐13‐1, C11‐13‐2). Fraction C11‐13‐2 (21.1 mg) was subjected Sephadex LH‐20 column (CHCl~3~: MeOH = 1:1) to afford compound **12** (5.4 mg, 87.3% area).

The ethyl acetate layer (53.2 g) was subjected to silica gel column eluted with *n*‐hexane: EtOAc (1:0 to 0:1, *v/v*) to obtain 10 fractions (E1 \~ E10). Compound **13** (1.9 mg, 63.6% area) was purified from fraction E1 (40.2 mg) by semi‐preparative HPLC (Phenomenex Luna 5 μm C18, 250 × 21.2 mm, 40% CH~3~CN) at 22 min.

11‐Methoxy polilsin A (**1**): White amorphous powder, $\left\lbrack \alpha \right\rbrack_{D}^{25}$ + 4.8 (*c* 0.1 CH~3~OH), UV (CH~3~OH) λ~max~ (log ε); 214 (3.01), HRESI‐MS ion peak at *m/z* 261.1103 \[M + Na\]^+^ (calcd for C~13~H~18~O~4~Na, 261.1097), ^1^H NMR data (Methanol‐*d* ~*4*~, 600 MHz): δ~H~ 6.99 (1H, m, H‐2), 3.71 (3H, s, OCH~3~‐11), 2.71 (1H, m, H‐9a), 2.59 (1H, m, H‐9b), 2.52 (1H, m, H‐6a), 2.37 (1H, m, H‐3a), 2.23 (1H, m, H‐8a), 2.18 (1H, m, H‐6b), 2.10 (1H, m, H‐3b), 2.03 (1H, m, H‐8b), 1.88 (1H, m, H‐5a), 1.87 (1H, m, H‐4), 1.36 (3H, s, H‐12), 1.29 (1H, m, H‐5b), ^13^C NMR data (Methanol‐*d* ~*4*~, 150 MHz): δ~C~ 179.5 (C‐10), 169.2 (C‐11), 140.1 (C‐2), 131.3 (C‐1), 90.5 (C‐7), 52.2 (OCH~3~‐11), 44.0 (C‐4), 32.0 (C‐8), 29.9 (C‐9), 28.1 (C‐3), 25.9 (C‐6), 24.3 (C‐5), 23.0 (C‐12).

13‐Methoxy Bisaborosaol F (**5**): Colorless syrup, $\left\lbrack \alpha \right\rbrack_{D}^{25}$ + 0.1 (*c* 0.1 CH~3~OH), UV (CH~3~OH) λ~max~ (log ε); 215 (3.47), HRESI‐MS ion peak at *m/z* 319.1885 \[M + Na\]^+^ (calcd for C~17~H~28~O~4~Na, 319.1880), ^1^H NMR data (DMSO‐*d* ~*6*~, 600 MHz): δ~H~ 6.93 (1H, m, H‐2), 5.62 (1H, dt, *J* = 15.6, 7.2, H‐11), 5.39 (1H, d, *J* = 15.6, H‐12), 3.63 (3H, s, OCH~3~‐7), 3.01 (3H, s, OCH~3~‐13), 2.37 (1H, m, H‐6a), 2.26 (1H, m, H‐3a), 2.14 (2H, d, *J* = 7.2, H‐9), 2.01 (2H, m, H‐3b, 6b), 1.81 (1H, m, H‐5a), 1.44 (1H, m, H‐4), 1.16 (3H, s, H‐14, 15), 1.12 (1H, m, H‐5b), 1.00 (3H, s, H‐10) ^13^C NMR data (DMSO‐*d* ~*6*~, 150 MHz): δ~C~ 166.7 (C‐7), 140.1 (C‐2), 137.4 (C‐12), 129.1 (C‐1), 126.0 (C‐11), 74.2 (C‐13), 72.0 (C‐8), 51.2 (OCH~3~‐7), 49.4 (OCH~3~‐13), 42.8 (C‐9), 41.5 (C‐4), 26.3 (C‐3), 25.8 (C‐14), 25.6 (C‐15), 24.8 (C‐6), 23.8 (C‐10), 22.6 (C‐5).

Rugosic acid A (**7**): Colorless syrup.$\ \left\lbrack \alpha \right\rbrack_{D}^{25}$ + 4.7 (*c* 0.1 CH~3~OH), ESI‐MS ion peaks at *m/z* 265 \[M -- H\] ^‐^, ^1^H NMR data (Chloroform‐*d*, 600 MHz): δ~H~ 9.52 (1H, s, H‐14), 6.83 (1H, dd, *J* = 6.0, 1.2, H‐3), 5.20 (1H, ddd, *J* = 5.4, 2.4, 1.2, H‐5), 4.51 (1H, dd, *J* = 11.4, 6.0, H‐2), 2.61 (1H, m, H‐11), 2.22 (1H, dd, *J* = 14.4, 5.4, H‐6a), 1.89 (1H, ddd, *J* = 10.8, 9.0, 2.4, H‐10), 1.82 (1H, m, H‐8a), 1.77 (1H, dd, *J* = 14.4, 2.4, H‐6b), 1.70 (1H, dd, *J* = 12.0, 6.0, H‐8b), 1.61 (1H, m, H‐9a), 1.43 (1H, m, H‐9b), 0.96 (3H, d, *J* = 6.6, H‐12), 0.92 (1H, d, *J* = 6.6, H‐13), 0.86 (1H, s, H‐15), ^13^C NMR data (Chloroform‐*d*, 150 MHz): δ~C~ 191.6 (C‐14), 150.0 (C‐3), 146.6 (C‐4), 95.1 (C‐1), 70.0 (C‐5), 69.0 (C‐2), 54.5 (C‐10), 42.1 (C‐8), 39.8 (C‐7), 38.6 (C‐6), 26.0 (C‐11), 25.0 (C‐12), 23.3 (C‐15), 20.2 (C‐9), 18.6 (C‐13).

2.3. Cell culture {#ptr6767-sec-0005}
-----------------

RAW 264.7 (ATCC TIB‐71) cells and Hep3B (ATCC HB‐8064) cells were cultured in Dulbecco\'s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin sulfate. Cells were maintained at 37°C in humidified air with 5% CO~2~.

2.4. Measurement of NO contents and cell cytotoxicity {#ptr6767-sec-0006}
-----------------------------------------------------

RAW 264.7 (ATCC TIB‐71) cells were cultured in Dulbecco\'s modified Eagle medium (DMEM), and NO assay was carried out for measurements of NO release using previously reported method (Su et al., [2019](#ptr6767-bib-0028){ref-type="ref"}). Briefly, RAW 264.7 cells were plated at 1 × 10^5^ cell density in 96‐well microplate, and cultured for 24 hr. Compounds (**1**--**13**) were pretreated with increasing dose concentrations (‐10 and 30 μM), and then stimulated with LPS (1 μg/mL, Sigma‐Aldrich, St. Louis, MO) for 18hr. The mixture of cell supernatant (100 μL) and Griess reagent \[1% sulfanilamide +0.1% N‐(1‐naphthyl)ethylenediamine (Sigma--Aldrich, St. Louis, MO)\] in 5% phosphoric acid was recorded at 550 nm using a microplate reader (Varioskan LUX, Thermo Fisher Scientific Inc., Waltham, MA). RAW 264.7 cell cytotoxicity was evaluated using 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay (Lim et al., [2019](#ptr6767-bib-0019){ref-type="ref"}).    

2.5. Real‐time PCR using Taqman probe {#ptr6767-sec-0007}
-------------------------------------

Total RNA was extracted from RAW 264.7 cells using the TaKaRa MiniBEST Universal RNA extraction Kit following the manufacturer\'s instructions (TaKaRa Bio Inc. Japan). The complementary DNA (cDNA) was synthesized from 1 μg of the total RNA using a PrimeScript first strand cDNA synthesis kit (Takara Bio Inc. Japan). Quantitative real‐time PCR (qPCR) of Il1bβ (Mm00434228_m1), Tnf (Mm00443258_m1), and Il6 (Mm00446190_m1) was performed with a Taqman Gene Expression Assay Kit (Thermo Fisher Scientific, San Jose, CA). To normalize the gene expression, an 18S rRNA endogenous control (Applied Biosystems, Foster City, CA) was used. The qPCR was employed to verify the mRNA expression using a Step‐One Plus Real‐Time PCR system. To quantify mRNA expression, Taqman mRNA assay was performed according to the manufacturer\'s protocol (Applied Biosystems) (Bertucci et al., [2019](#ptr6767-bib-0003){ref-type="ref"}). PCR amplification was analyzed using the comparative ΔΔCT method.

2.6. Immunoblots analysis {#ptr6767-sec-0008}
-------------------------

The whole cell lysate was extracted using Cell Lysis Buffer (Cell Signaling Technology, Beverly, MA). The cytosolic and nuclear extracts were prepared using an NE‐PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific) according to the manufacturer\'s protocol. Immunoblots analysis was performed as previously described method (Jang et al., [2017](#ptr6767-bib-0016){ref-type="ref"}). After transfer to nitrocellulose (NC) membrane, the blocking membrane with 5% skimmed milk powder was incubated overnight at 4°C with primary antibody, including anti‐p65 NF‐κB (1:1000), anti‐IκBα (1:1000), anti‐iNOS (1:1000), anti‐lamin B (1:1000), and anti‐β‐actin antibodies (Cell Signaling Technology, Beverly, MA). The membranes were then incubated with a horseradish peroxide‐conjugated anti‐rabbit secondary antibody (1:5000) at room temperature. The band densities were calculated with Quantity One software (Bio‐Rad Laboratories, Hercules, CA).

2.7. Immunocytochemistry {#ptr6767-sec-0009}
------------------------

RAW 264.7 (1 × 10^6^ per well) cells were seeded on collagen‐coated coverslips in 6‐well plates and incubated overnight. Then, the cells were pretreated with compound 7 (30 μM) or dexamethasone (10 μM) for 2 hr. Then, the coverslips were washed with phosphate‐buffered saline (PBS) and fixed with ice‐cold methanol for 10 min at room temperature. After blocking with 1% bovine serum albumin (BSA) in PBS containing 0.1% Tween 20 (PBST) for 30 min, the coverslips were incubated overnight with an anti‐p65 NF‐κB antibody in a humidified chamber at 4°C, followed by coincubation with a FITC‐labeled anti‐rabbit IgG antibody in a 37°C humidified chamber for 60 min in the dark. The coverslips were sealed and stained with DAPI by using ProLong Gold antifade reagent with DAPI (Thermo Fisher Scientific, Waltham, MA). Immunofluorescence images were obtained using an Olympus IX73 microscope with cellSens software (Olympus, Center Valley, PA) (Lim et al., [2019](#ptr6767-bib-0019){ref-type="ref"}).

2.8. pSTAT3 luciferase assay {#ptr6767-sec-0010}
----------------------------

Hep3B cells stably expressing pSTAT3‐Luc were established as described previously (Hwang et al., [2016](#ptr6767-bib-0015){ref-type="ref"}; Oh et al., [2014](#ptr6767-bib-0025){ref-type="ref"}). In brief, Hep3B cells stably expressing pSTAT3‐Luc were seeded in 96‐well culture plates at 2 × 10^4^ cells/well, and cells were treated with samples for 1 hr before stimulation with IL‐6 (10 ng/mL) for 12 hr. Luciferase activity was measured according to the manufacturer\'s protocol (Promega Corp., Madison, WI).

2.9. Animals {#ptr6767-sec-0011}
------------

Female BALB/c mice (6 weeks old) were purchased from Orient Bio (Gwangju, Korea). All animals had ad libitum access to a standard rodent chow and filtered water during the study. The animals were housed six per cage in a laminar air flow room maintained under a temperature of 24°C, relative humidity of 55%, and a 12 hr light/dark cycle throughout the study. The care and treatment of the animals were carried out in accordance with the guidelines established by the Public Health Service Policy on the Humane Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the Korea Research Institute of Bioscience and Biotechnology. Approved number of animal experiment was KRIBB‐AEC‐20033.

2.10. Isolation of bronchoalveolar lavage in LPS‐induced acute lung injury {#ptr6767-sec-0012}
--------------------------------------------------------------------------

BALB/C mice (female, 6 weeks) were randomly divided into 5 groups and each group contained six mice: control, LPS, LPS + RA (10 μg/kg and 1 μg/kg), and LPS + DX (5 mg/kg, positive control). RA and DX were orally administrated as a pretreatment for 24 hr. Then, acute lung injury (ALI) in all mice were induced by intratracheally injection of LPS (1 mg/mL, 25 μL) after anesthesia by intraperitoneal injection of tribromoethanol. After 5 hr of LPS treatment, the mice were euthanized by CO~2~ inhalation, and their bronchoalveolar lavage fluid (BALF) was collected.

2.11. Measurement of myeloperoxidase concentration {#ptr6767-sec-0013}
--------------------------------------------------

Myeloperoxidase (MPO) concentration in lung tissues represents pulmonary infiltration of inflammatory cells, such as neutrophils and macrophages. MPO concentration in BALF of lung tissues was measured using commercial kits (DY3667) purchased from R&D SYSTEMS INC (MN, USA).

3. RESULTS AND DISCUSSION {#ptr6767-sec-0014}
=========================

3.1. Identification of compounds {#ptr6767-sec-0015}
--------------------------------

Fractionation and chromatographic separation of *R. rugosa* Thunb. led to the purification of 13 compounds, including eight sesquiterpenoids (**1** \~ **8**), five triterpenoids (**9** \~ **13**) from the n‐hexane, CHCl~3~ and EtOAc‐soluble fractions. By means of LC--MS analysis and 1D and 2D NMR, the structures of these compounds were identified to be 11‐methoxy polisin A (**1**) (Wang, Li, Dong, Liu, & Feng, [2013](#ptr6767-bib-0032){ref-type="ref"}), bisaborosaol B1, 2 (**2**, **3**) (Hashidoko, Tahara, & Mizutani, [1991](#ptr6767-bib-0010){ref-type="ref"}), bisaborosaol F, E1/E2, 13‐methoxy bisaborosaol F (**4**, **5**, **6**) (Hashidoko, Tahara, & Mizutani, [1993](#ptr6767-bib-0011){ref-type="ref"}), rugosic aicd A, D (**7**, **8**) (Hashidoko et al., [1991](#ptr6767-bib-0010){ref-type="ref"}), oleanolic acid acetate (**9**) (Hichri, Jannet, Cheriaa, Jegham, & Mighri, [2003](#ptr6767-bib-0013){ref-type="ref"}), ursolic acid (**10**) (Seebacher, Simic, Weis, Saf, & Kunert, [2003](#ptr6767-bib-0026){ref-type="ref"}), corosolic acid (**11**) (Hou et al., [2009](#ptr6767-bib-0014){ref-type="ref"}), *trans*‐, *sis*‐jacumaric acid (**12**, **13**) (Häberlein & Tschiersch, [1994](#ptr6767-bib-0008){ref-type="ref"}).

Compound **1** was obtained as a white amorphous powder, $\left\lbrack \alpha \right\rbrack_{D}^{25}$ + 4.8 (*c* 0.1 CH~3~OH). The molecular formula of **1** is C~13~H~18~O~4~, as determined by HRESI‐MS analysis (*m/z* 261.1103 \[M + Na\]^+^, calcd for C~13~H~18~O~4~Na, 261.1097). The UV spectrum showed absorption peaks at 214 nm. ^1^H NMR data exhibited signals for a methyl group \[δ~H~ 1.36 (s, H‐12)\], and a methoxy group \[δ~H~ 3.71 (s, 11‐OCH~3~)\]. The ^13^C and DEPT 135 NMR data showed 13 signals corresponding to a methyl carbon \[δ~C~ 22.9 (C‐12)\], five methylene carbons \[δ~C~ 24.2 (C‐5), 25.9 (C‐6), 28.0 (C‐3), 29.9 (C‐9), 32.0 (C‐8)\], a methine carbon \[δ~C~ 44.0 (C‐4)\], a methoxy carbon \[δ~C~ 52.2 (11‐OCH~3~)\], a sp^2^ carbon \[δ~C~ 140.1 (C‐2)\], and two carbonyl carbons \[δ~C~ 169.2 (C‐11), 179.5 (C‐10)\]. The ^1^H‐^1^H COSY spectrum showed that the proton at H‐2 correlated with the methylene proton at δ~H~ 2.37, 2.10 (H‐3), H‐3 correlated with the methylene proton at δ~H~ 1.87 (H‐4), H‐6 correlated with the methylene proton at δ~H~ 1.88, 1.29, (H‐5) and H‐9 correlated with the methylene proton at δ~H~ 2.23, 2.03 (H‐8). Additionally, the HMBC spectrum showed correlations from δ~H~ 3.71 (11‐OCH~3~) to δ~C~ 169.2 (C‐11) indicating the position of methoxy group. The HMBC correlations from δ~H~ 3.71 (11‐OCH~3~) to δ~C~ 131.3 (C‐1) suggested that the 11‐OCH~3~ was connected to the C‐1. The connectivities of ring A were identified by HMBC correlations from δ~H~ 6.99 (H‐2) to δ~C~ 25.9 (C‐6), from δ~H~ 2.52, 2.18 (H‐6) to δ~C~ 131.3 (C‐1), from δ~H~ 1.88, 1.29 (H‐5) to δ~C~ 44.0 (C‐4) and ^1^H‐^1^H COSY correlations. In addition, the HMBC correlations from δ~H~ 2.23, 2.03 (H‐8) to δ~C~ 90.5 (C‐7), 29.9 (C‐9), 179.5 (C‐10) and correlations from δ~H~ 2.71, 2.59 (H‐9) to δ~C~ 90.5 (C‐7), 179.5 (C‐10) suggested the presence of a lactone ring B. The connection between ring A and ring B was constructed by the HMBC correlations from δ~H~ 1.36 (H‐12) to δ~C~ 44.0 (C‐4), 90.5 (C‐7), 32.0 (C‐8), from δ~H~ 1.87 (H‐4) to δ~C~ 90.5 (C‐7) and from δ~H~ 2.23, 2.03 (H‐8) to δ~C~ 44.0 (C‐4) as shown in Figure [1b](#ptr6767-fig-0001){ref-type="fig"}. The compound **1** was finally identified as 11‐methoxy polisin A (Figure [1a](#ptr6767-fig-0001){ref-type="fig"}).

![Terpenoid structures and new methoxy structures in *R. rugosa* extracts. (a) Structure of isolated compounds **1--13** of *R. rugosa*. (b) Key ^1^H‐^1^H COSY and HMBC correlations of **1** (c) Key ^1^H‐^1^H COSY and HMBC correlations of **5**](PTR-9999-na-g001){#ptr6767-fig-0001}

Compound **5** was obtained as a Colorless syrup, $\left\lbrack \alpha \right\rbrack_{D}^{25}$ + 1 (*c* 0.1 CH~3~OH). The molecular formula of **5** is C~17~H~28~O~4~, as determined by HRESI‐MS analysis (*m/z* 319.1885 \[M + Na\]^+^, calcd for C~17~H~28~O~4~Na, 319.1880). The UV spectrum showed absorption peaks at 215 nm. ^1^H NMR data exhibited signals for three methyl groups \[δ~H~ 1.00 (s, H‐10), 1.16 (s, H‐14, H‐15)\], two methoxy groups \[δ~H~ 3.63 (s, 7‐OCH~3~), 3.01 (s, 13‐OCH~3~)\], and two *trans*‐conjugated olefinic protons \[δ~H~ 5.62 (dt, *J* = 15.6, 7.2 Hz, H‐11), 5.39 (d, *J* = 15.6 Hz, H‐12)\]. Since the H‐11 were further coupled vicinally with H‐9(δ~H~ 2.14, d, *J* = 7.2 Hz), partial structure \[---CH~2~---CH=CH---\] became feasible. The ^13^C, DEPT 90 and DEPT 135 NMR data showed 17 signals corresponding to three methyl carbons \[δ~C~ 23.8 (C‐10), 25.6 (C‐15), 25.8 (C‐14)\], four methylene carbons \[δ~C~ 22.6 (C‐5), 24.8 (C‐6), 26.3 (C‐3), 42.8 (C‐9)\], a methine carbon \[δ~C~ 41.5 (C‐4)\], two methoxy carbons \[δ~C~ 49.4 (13‐OCH~3~), 51.2 (11‐OCH~3~)\], three sp^2^ carbons \[δ~C~ 125.9 (C‐11), 137.4 (C‐12), 140.1 (C‐2)\], and a carbonyl carbon \[δ~C~ 166.7, (C‐7), 179.5, (C‐10)\]. The ^1^H‐^1^H COSY spectrum showed that the proton at H‐2 correlated with the methylene proton at δ~H~ 2.26, 2.01 (H‐3), H‐3 correlated with the methine proton at δ~H~ 1.44 (H‐4), H‐4 correlated with the methylene proton at δ~H~ 1.81, 1.21 (H‐5) and H‐5 correlated with the methylene proton at δ~H~ 2.37, 2.01 (H‐6). The ^1^H‐^1^H COSY spectrum clearly revealed the presence of a cyclohexene. Additionally, the HMBC spectrum showed correlations from δ~H~ 3.63 (7‐OCH~3~) to δ~C~ 166.7 (C‐7) and from δ~H~ 3.01 (13‐OCH~3~) to δ~C~ 74.1 (C‐13) indicating the position of two methoxy groups. The HMBC correlations from δ~H~ 1.16 (H‐14, H‐15) to δ~C~ 137.4 (C‐12), 74.1 (C‐13), from δ~H~ 2.14 (H‐9) to δ~C~ 125.9 (C‐11) and correlations from δ~H~ 1.00 (H‐10) to δ~C~ 41.5 (C‐4), 71.9 (C‐8), 42.8 (C‐9) confirmed the side chain of the compound **5**. (Figure [1c](#ptr6767-fig-0001){ref-type="fig"}). The compound **5** was finally identified as 13‐methoxy bisaborosaol F. (Figure [1a](#ptr6767-fig-0001){ref-type="fig"}).

3.2. Inhibitory effect of nitric oxide production in *R. rugosa* extract {#ptr6767-sec-0016}
------------------------------------------------------------------------

NO is a major pro‐inflammatory mediator, involved in the pathogenesis of inflammation (Sharma, Al‐Omran, & Parvathy, [2007](#ptr6767-bib-0027){ref-type="ref"}). During an inflammatory response, the large amount of NO formed by the action of iNOS surpasses the standard physiological amount of NO (Xie, Kashiwabara, & Nathan, [1994](#ptr6767-bib-0033){ref-type="ref"}). A previous study reported that *R. rugosa* extracts of 50% EtOH had main active substituents; gallic acid and ellagic acid, and anti‐inflammatory effects by inhibiting NF‐κB and MAPK activation (Tursun et al., [2016](#ptr6767-bib-0030){ref-type="ref"}). However, the efficacy of *R. rugosa* extracts of 95% EtOH and the specific active compound responsible for the inflammatory effects became unclear. Then, we evaluated NO production in LPS‐induced RAW 264.7, a mouse macrophage cell line, upon treatment with *R. rugosa* of 95% EtOH extract and its terpenoid compounds (Figure [2](#ptr6767-fig-0002){ref-type="fig"}). *R. rugosa* of 95% EtOH extract dose‐dependently decreased NO production under LPS stimulation (Figure [2a](#ptr6767-fig-0002){ref-type="fig"}). In addition, to find active compound of inhibitory effect of NO production, we tested 13 compounds of terpenoid structure derived from *R. rugosa* of 95% EtOH extract (Figure [2b](#ptr6767-fig-0002){ref-type="fig"}). Through screening terpenoid compounds in *R. rugosa* of 95% EtOH extract, we observed highly inhibitory effect of NO production and selected rugosic acid A, oleanolic acid acetate, and ursolic acid. These results suggested that *R. rugosa* of 95% EtOH extract had inhibitory effect of NO production similar to dexamethasone, and its major active compounds were rugosic acid A, oleanolic acid acetate, and ursolic acid.

![Anti‐inflammatory effect of *R. rugosa* extract and Rugosic acid A in RAW 264.7 cell line. (a) NO concentration was evaluated in *R. rugosa* extract. (b) The inhibition screening of NO production was evaluated among 13 constituents in *R. rugosa* extract. NO evaluation performed triplicate test, and results described as Mean ± SE. An unpaired Student\'s *t* test was used for statistical analysis. \#\#\#*p* \< .001 versus Con. \*\**p* \< .01, \*\*\**p* \< .001, versus LPS. Con; control, LPS; lipopolysaccharide, Dx; dexamethasone. (c) Rugosic acid Adecreased iNOS expression levels in LPS‐induced RAW 264.7 cells. (d) Relative ratio of iNOS versus β‐actin were measured using densitometry, and dexamethasone was used as positive control. These graphs represented that rugosic acid A dose‐dependently inhibited iNOS at concentration of 1, 10, and 30 μM using Immunoblots analysis. (e‐g) The mRNA expression levels of IL‐1β, TNF‐α, and IL‐6 were measured using quantitative real‐time PCR experiment, and these pro‐inflammatory cytokines were significantly diminished by rugosic acid A. Cells were pre‐incubated for 2 hr with rugosic acid A at concentration of 30 μM, and activated by LPS (1 μg/mL) for 2 hr. Results represent as mean ± SE, and dexamethasone was used as a positive control. \#\#*p* \< .01, \#\#\#*p* \< .001 versus Con, \**p* \< .05, \*\**p* \< .01, and \*\*\**p* \< .001 versus LPS. Con; control, LPS; lipopolysaccharide, Dx; dexamethasone, RA; rugosic acid. (h) Immunoblots analysis displayed that translocation of NF‐κB into nucleus and degradation of cytosolic IκBα were suppressed by rugosic acid (30 μM) in RAW 264.7 cells. (i) Rugosic acid (30 μM) suppressed nuclear translocation of NF‐κB. After 2 hr of compound 20 treatment, the cells were fixed and permeabilized. NF‐κB (green) was immunostained with rabbit‐anti‐NF‐κB followed by FITC‐conjugated secondary antibodies and the nuclei (blue) were stained with DAPI. The results shown were representative of two independent experiments \[Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](PTR-9999-na-g002){#ptr6767-fig-0002}

3.3. Inhibitory activities of iNOS, pro‐inflammatory cytokines, and NF‐κB by rugosic acid A {#ptr6767-sec-0017}
-------------------------------------------------------------------------------------------

iNOS, which is involved in the production of NO, is a novel signaling molecule associated with the MAPK pathway and NF‐κB activity in both microglia and macrophage cells (Tripathi, Tripathi, Kashyap, & Singh, [2007](#ptr6767-bib-0029){ref-type="ref"}). Subsequently, pro‐inflammatory cytokines such as IL‐1β, TNF‐α, and IL‐6 are induced by activating nuclear translocation of NF‐κB (Liu et al., [2017](#ptr6767-bib-0021){ref-type="ref"}).

To investigate intracellular biological evidence of reduced NO level by rugosic acid A, we evaluated the effect of rugosic acid A on the pro‐inflammatory mediators such as iNOS, IL‐1β, TNF‐α, IL‐6, and in LPS‐induced macrophages (Figure [2c‐g](#ptr6767-fig-0002){ref-type="fig"}). In our results, rugosic acid A was newly developed inhibition of iNOS under LPS‐induced macrophages based on western blotting (Figure [2c](#ptr6767-fig-0002){ref-type="fig"}). The graph described significantly inhibition of iNOS (Figure [2d](#ptr6767-fig-0002){ref-type="fig"}). The inhibitory effect of rugosic acid A (30 μM) was similar to that of dexamethasone (positive control, 10 μM). Moreover, we tested pro‐inflammatory cytokines after treatment with rugosic acid A. Rugosic acid A (30 μM) significantly inhibited the pro‐inflammatory cytokine mRNA of IL‐1β, and TNF‐α, and IL‐6. Specially, rugosic acid A had the more effective prevention of mRNA of IL‐6 than dexamethasone (Figure [2e‐g](#ptr6767-fig-0002){ref-type="fig"}).

Subsequently, we evaluated preventive effect of nuclear translocation of NF‐κB by pretreatment with rugosic acid A quantitatively and qualitatively (Figure [2h,i](#ptr6767-fig-0002){ref-type="fig"}). To determine whether rugosic acid A suppressed the nuclear translocation of NF‐κB, we evaluated nuclear NF‐κB and cytosolic IκBα using western blotting (Figure [2h](#ptr6767-fig-0002){ref-type="fig"}). Immunocytochemistry clearly demonstrated that rugosic acid A reduced the translocation of NF‐κB into the nucleus in RAW 264.7 cells (Figure [2i](#ptr6767-fig-0002){ref-type="fig"}). Rugosic acid A remarkably ameliorated to translocate nuclear NF‐κB by suppressing the degradation of IκBα, similar to dexamethasone. These results suggested that, rugosic acid A was significant anti‐inflammatory compound by inhibition of nuclear translocation of NF‐κB among terpenoid structures in *R. rugosa* extracts (95% EtOH).

3.4. Inhibition of IL‐6/STAT3 activation by rugosic acid A {#ptr6767-sec-0018}
----------------------------------------------------------

To further conduct strong inhibition of IL‐6 after rugosic acid treatment in RAW 264.7, we tested to discover potent STAT3 inhibitor among major substituents; rugosic acid (compound **7**), oleanolic acid acetate (compound **9**), and ursolic acid (compound **10**) in *R. rugosa* extracts under IL‐6 mediated STAT3 activation in Hep3B cell line, which was co‐transfected with pSTAT3‐Luc and pcDNA3.1/Hygro vector (Oh et al., [2014](#ptr6767-bib-0025){ref-type="ref"}). Using IL‐6/STAT3 screening system of the transfected Hep3B cell line, we already reported that oleanolic acid acetate was major inhibitor of IL‐6/STAT3 activation (Hwang et al., [2016](#ptr6767-bib-0015){ref-type="ref"}). In previous study, ursolic acid had prevention of hepatic carcinoma by inhibition of STAT3 signaling pathway (Liu, Li, Li, & Lin, [2010](#ptr6767-bib-0022){ref-type="ref"}). In this study, we originally observed that rugosic acid significantly inhibited IL‐6‐mediated STAT3 activation (Figure [3a](#ptr6767-fig-0003){ref-type="fig"}). The IC50 value of IL‐6/STAT3 activation was represented on Figure [3b‐d](#ptr6767-fig-0003){ref-type="fig"}. These results suggested that rugosic acid similar to oleanolic acid acetate and ursolic acid had significant effect of IL‐6‐mediated STAT3 activation.

![Rugosic acid ameliorated IL‐6‐mediated STAT3 activation under transfected Hep3B cell line. (a) Inhibitory evaluation of IL6‐mediated STAT3 activation was evaluated by treatment with rugosic acid A, oleanolic acid acetate, and ursolic acid the transfected Hep3B cell line. (b‐d) Dose dependent curves about rugosic acid A (b), oleanolic acid acetate (c), and ursolic acid (d) were exhibited \[Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](PTR-9999-na-g003){#ptr6767-fig-0003}

3.5. Inhibition of phosphorylation of NF‐κB and STAT3 by rugosic acid A under acute lung injury model {#ptr6767-sec-0019}
-----------------------------------------------------------------------------------------------------

To further evaluate inhibitory effect of NF‐κB and STAT3 by rugosic acid A, we established LPS‐mediated acute lung injury (ALI) model and tested oral treatment with rugosic acid A (Figure [4a](#ptr6767-fig-0004){ref-type="fig"}). Because recent severe acute respiratory syndrome of coronavirus disease 2019 (COVID‐19) has rapidly spread in worldwide and has similar symptom with acute pneumonia accompanied by cytokine storm (Mehta et al., [2020](#ptr6767-bib-0023){ref-type="ref"}). If rugosic acid A may ameliorate symptom of acute pneumonia by inhibition of NF‐κB and STAT3, it will be alternative treatment with COVID‐19 similar to tocilizumab, which is an agent of recombinant humanized anti‐human IL‐6 receptor monoclonal antibody, and used to cure severe COVID‐19 patients by inhibiting IL‐6 signaling transduction, before development of vaccine of COVID‐19 (Xu et al., [2020](#ptr6767-bib-0034){ref-type="ref"}). Firstly, we performed evaluation of myeloperoxidase (MPO) concentration in BALF on ALI model, because MPO was used as biomarker of activation and accumulation of neutrophils in lung tissues and clinical signature of pneumonia patients (Abul et al., [2001](#ptr6767-bib-0001){ref-type="ref"}). We observed that pretreatment of rugosic acid A (10 μg/mL) significantly ameliorated LPS‐mediated MPO concentration (Figure [4b](#ptr6767-fig-0004){ref-type="fig"}). Subsequently, we evaluated preventive effect of phosphorylation of STAT3 and p65 NF‐κB by pretreatment with rugosic acid A using western blotting in lung tissue (Figure [4c](#ptr6767-fig-0004){ref-type="fig"}). In our results, the administration of rugosic acid A (10 μg/mL) had significantly inhibition of phosphorylation of STAT3 (Figure [4d](#ptr6767-fig-0004){ref-type="fig"}) and p65 NF‐κB (Figure [4e](#ptr6767-fig-0004){ref-type="fig"}) in lung tissues. These results suggested that rugosic acid A ameliorated LPS‐mediated ALI by decreasing MPO concentration and inhibiting phosphorylation of STAT3 and p65 NF‐κB.

![Effect of rugosic acid A on MPO activity in lung tissues of LPS‐stimulated ALI mice. (a) Schematic figure of induction of acute lung injury (ALI) mice. (b) After orally pretreatment with agents: RA 10 μg/kg, RA 1 μg/kg, and DX 5 mg/kg for 24 hr, mice intratracheally were injected with LPS (1 mg/mL, 25 μL). Vehicle group were orally administrated with PBS. The lung myeloperoxidase (MPO) concentration was determined on bronchoalveolar lavage fluid (BALF) after LPS injection. The values are presented as mean ± SE (*n* = 5 in each group). Multifactor ANOVA with Tukey\'s multiple comparison was used for statistical analyses; \#\#\#*p* \< .001, versus control group. \**p* \< .05, and \*\**p* \< .01, versus LPS group. (c) Expression of phosphorylated STAT3, p65 NF‐κB, total STAT3, total p65 NF‐κB and β‐actin in lung tissue. (d) Quantitative densitometry analysis of the ratio of phos‐STAT3 to total STAT3. (e) Quantitative densitometry analysis of the ratio of phos‐p65 NF‐κB to total p65 NF‐κB. \#\#\#*p* \< .001, versus control group. \**p* \< .05, \*\**p* \< .01 and \*\*\**p* \< .001, versus LPS group \[Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](PTR-9999-na-g004){#ptr6767-fig-0004}

3.6. Quantitative analysis of rugosic acid A in *R. rugosa* extracts {#ptr6767-sec-0020}
--------------------------------------------------------------------

To investigate yield value of rugosic acid A as an anti‐inflammatory agent, we performed quantitative analysis (Figure [5](#ptr6767-fig-0005){ref-type="fig"}). The sesquiterpenoid structure rugosic acid A was exhibited (Figure [5a](#ptr6767-fig-0005){ref-type="fig"}) and evaluated using calibration curve as a standard (Figure [5b](#ptr6767-fig-0005){ref-type="fig"}). In quantitative study, *R. rugosa* extracts (375.9 g) contained 0.8 mg/g of rugosic acid A (Figure 5c and *2.3 Extraction and isolation*).

![Quantitative analysis of rugosic acid A in *R. rugosa* extract. (a) Structure of rugosic acid A. (b) Calibration curve of rugosic aicd A standard. (c) HPLC chromatogram pattern of rugosic acid A in extract from hexan fraction of *R.rugosa*.; HPLC model: Agilent 1100series (Agilent), column: Phenomenex Luna C18 (5 μm, 4.6 × 250 mm), column temperature: 25°C, mobile phase: (a) H~2~O, (b) ACN, gradient: 0--0, 5--0, 45--100, 65(min)‐100(B%) \[Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](PTR-9999-na-g005){#ptr6767-fig-0005}

4. CONCLUSIONS {#ptr6767-sec-0021}
==============

Our group originally found that rugosic acid A, which has sesquiterpenoid structure has bioactivity responsible for the anti‐inflammatory activity of *R. rugosa* extract (EtOH 95%) by inhibition of the nuclear translocation of NF‐κB, by reduction of pro‐inflammatory mediators such as iNOS, TNF‐α, and IL‐6. Rugosic acid A significantly showed similar to major STAT3 inhibitory phytochemicals; oleanolic acid acetate and ursolic acid. In addition, our group measured quantitative analysis of rugosic acid A in *R. rugosa* extract (EtOH 95%). These results indicate that *R. rugosa* extract and its sesquiterpenoid compound, rugosic acid, may be safe and potential therapeutic agent for inflammatory diseases associated with NF‐κB and IL‐6/STAT3 signaling.
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